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The transcription factor NF-E2 p45-related factor 2 (Nrf2) and its negative regulator Kelch-like ECH associated
protein 1 (Keap1) control the expression of nearly 500 geneswith diverse cytoprotective functions. Keap1, a sub-
strate adaptor protein for Cullin3/Rbx1 ubiquitin ligase, normally continuously targets Nrf2 for degradation, but
loses this ability in response to electrophiles and oxidants (termed inducers). Consequently, Nrf2 accumulates
and activates transcription of its downstream target genes. Many inducers are phytochemicals, and cruciferous
vegetables represent one of the richest sources of inducer activity among themost commonly used edible plants.
Here we summarize the discovery of the isothiocyanate sulforaphane as a potent inducer which reacts with cys-
teine sensors of Keap1, leading to activation of Nrf2. We then describe the development of a quantitative Förster
resonance energy transfer (FRET)-based methodology combined with multiphoton fluorescence lifetime imag-
ing microscopy (FLIM) to investigate the interactions between Keap1 and Nrf2 in single live cells, and the effect
of sulforaphane, and other cysteine-reactive inducers, on the dynamics of the Keap1–Nrf2 protein complex. We
present the experimental evidence for the “cyclic sequential attachment and regeneration” or “conformation cy-
cling”model of Keap1-mediated Nrf2 degradation. Finally, we discuss the implications of thismode of regulation
of Nrf2 for achieving a fine balance under normal physiological conditions, and the consequences and mecha-
nisms of disrupting this balance for tumor biology.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
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Introduction
The Keap1/Nrf2 pathway
Cells have evolved multiple mechanisms to protect themselves
under conditions of stress. One major protective mechanism comprises
a network of functionally diverse inducible proteins, such as NAD(P)H:
quinone oxidoreductase 1 (NQO1), heme oxygenase 1, glutathione
transferases (GSTs), aldo-keto reductases, γ-glutamylcysteine ligase,
thioredoxin, and thioredoxin reductase. The gene expression of these
proteins is regulated by transcription factor NF-E2 p45-related factor 2
(Nrf2, gene name NFE2L2) (Itoh et al., 1997). Under homeostatic
(basal) conditions, Nrf2 binds to its major negative regulator, Kelch-
like ECH associated protein 1 (Keap1) (Itoh et al., 1999), which forms a
RING E3-ubiquitin ligase with Cullin (Cul)3/Rbx1 and continuously tar-
gets the transcription factor for ubiquitination and proteasomal degrada-
tion (Cullinan et al., 2004; Kobayashi et al., 2004; Zhang et al., 2004).
In response to electrophiles and oxidants (termed inducers), which
recognize and chemically modify specific cysteine residues of Keap1,
ubiquitination of Nrf2 is inhibited (McMahon et al., 2010). Consequently,
Nrf2 accumulates and activates transcription, ultimately leading to en-
hanced expression of nearly 500 genes encoding drug-metabolizing, an-
tioxidant, and anti-inflammatory proteins aswell as enzymes involved in
intermediary metabolism (Baird and Dinkova-Kostova, 2011; Hayes
et al., 2010; Kensler et al., 2007; Malhotra et al., 2010; Mitsuishi et al.,
2012a;Mitsuishi et al., 2012b; Singh et al., 2013). The coordinate expres-
sion of Nrf2 target genes results in enhanced protection against various
types of stresses and restores homeostasis.
Nrf2 is a 605 aa protein which has seven functional domains named
Neh1-7 (Nrf2–ECHhomology) (Fig. 1A) (Itoh et al., 1999). Neh1 contains
the bZip DNA binding and heterodimerization domain through which
Nrf2 forms a heterodimer with a small Maf transcription factor. The
Nrf2/small Maf heterodimer binds to the antioxidant response element
(ARE), also known as the electrophile response element (EpRE), the up-
stream regulatory sequence found in the promoter of cytoprotective
genes. The Neh2 domain is a negative regulatory domain through
which Nrf2 binds to Keap1. The Neh3 domain binds to the chromo-
ATPase/helicase DNA binding protein family member CHD6, a transcrip-
tional co-activator (Nioi et al., 2005). The Neh4 and Neh5 domains act
synergistically to bind CBP, another transcriptional co-activator (Katoh
et al., 2001). The Neh6 domain represents a second negative regulatory
domain which mediates Keap1-independent degradation of Nrf2
(Chowdhry et al., 2013; McMahon et al., 2004; Rada et al., 2012). A
third negative regulatory region is the Neh7 domain, through which
Nrf2 interacts with the retinoid X receptor alpha (RXRα) (Wang et al.,
2013).
Keap1 is a 624 aa multi-domain protein (Fig. 1B) which contains:
(i) an N-terminal region (NTR, amino acids 1–60), (ii) a BTB domain
(amino acids 61–179), through which Keap1 forms a homodimer and
also interacts with Cul3, (iii) an intervening region (IVR, amino acids
180–314), which is especially cysteine-rich and contains 8 cysteine res-
idues among its 134 amino acids, (iv) a Kelch domain, comprising six
Kelch motifs (amino acids 315–359, 361–410, 412–457, 459–504,
506–551, and 553–598), through which Keap1 binds Nrf2, and (v) a
C-terminal region (CTR, amino acids 599–624). Monomeric Nrf2 binds
to dimeric Keap1 via two motifs residing in the N-terminal Neh2 do-
main of the transcription factor, the “DLG” and the “ETGE” motif
(Fig. 1A), whereby the affinity for the ETGE motif is 200-fold greater
than for the DLG (McMahon et al., 2006; Tong et al., 2006a). These mo-
tifs form β-turn structures which bind via electrostatic interactions be-
tween their acidic aspartate and glutamate residues with arginine
residues 380, 415, and 483 in the Keap1 Kelch domain. Critically, both
motifs are required for Keap1-mediated ubiquitination of Nrf2 by
Cul3–Rbx1 (McMahon et al., 2006).
Discovery of sulforaphane as an inducer of cytoprotective enzymes
Sulforaphane [1-isothiocyanato-(4R)-(methylsulfinyl)butane] (Fig. 2)
is an isothiocyanate which was isolated from broccoli extracts in Paul
Talalay's laboratory as the principal inducer of the cytoprotective enzyme
NQO1 by use of a quantitative bioassay-guided fractionation approach
(Zhang et al., 1992). The isolation of sulforaphane was consequent to
the finding that extracts of broccoli (Brassica oleracea italica) represent
one of the richest sources of inducer activity among a large series of
extracts prepared from the most commonly used edible plants that be-
long to 10 different plant families covering almost the entire spectrum
of vegetables consumed in Europe and the USA (Prochaska et al., 1992).
In the intact plant, sulforaphane is present as a precursor, the gluco-
sinolate glucoraphanin (Fig. 2) (Fahey et al., 2001; Talalay and Fahey,
2001). The same plant also contains a β-thioglucosidase enzyme,
known as myrosinase (EC 3.2.1.147) which, under physiological condi-
tions, is physically separated from its glucosinolate substrate. However,
upon damage of the plant tissue such as injury or chewing, enzyme and
substrate come in contact, resulting in highly efficient hydrolysis of
the relatively biologically inert glucosinolate to form a variety of reac-
tive products with critical functions for plant defense (Halkier and
Gershenzon, 2006). Isothiocyanates, such as sulforaphane, represent
one of the major types of products of the myrosinase reaction, and are
responsible for the majority of the biological activities that have been
associated with glucosinolates.
The central carbon of the isothiocyanate (\N_C_S) group is electro-
philic and reacts readily with sulfur-, nitrogen-, and oxygen-centered
Fig. 1.Domain structure of Nrf2 (A) and Keap1 (B). (A) In Nrf2, the positions of the seven functional domains Neh1-7 are shown. Neh1 contains the DNA binding and heterodimerization
domain. The Neh2 domain is the main negative regulatory domain of Nrf2 through which it binds to Keap1 via the DLG and ETGEmotifs. The Neh3, Neh4 and Neh5 domains bind to the
transcriptional co-activators CHD6 and CBP. The Keap1-independent degradation of Nrf2 is mediated through the Neh6 domain. Nrf2 binds to the retinoid X receptor alpha (RXRα)
through the Neh7 domain. (B) In Keap1, five functional domains are shown. Keap1 dimerization and Cul3 binding aremediated by the BTB domain. The intervening region (IVR) contains
a number of reactive cysteine residues through which Nrf2 activity is regulated, including C226, C273 and C288. The Kelch domain forms a 6-bladed β-propeller structure through which
Keap1 binds to the Neh2 domain of Nrf2, and to the KIR domain of p62, among other proteins.
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nucleophiles. Such nucleophiles are containedwithin amino acids; conse-
quently, proteins and peptides are the major cellular targets of isothiocy-
anates [reviewed in (Mi et al., 2011; Zhang, 2012)]. In particular, cysteine
residues with low pKa values are especially reactive with isothiocyanates
as they exist as thiolate anions even at physiological pH, and are thus
primed for nucleophilic attack on the electrophilic substrate. As Keap1 is
equipped with reactive cysteine residues, it serves as the cellular sensor
for electrophiles, including isothiocyanates. Indeed, by use of UV–VIS
spectroscopy cysteine modifications within Keap1 were shown to occur
when the recombinant murine protein was incubated with sulforaphane
(Dinkova-Kostova et al., 2002). By use of mutagenesis analysis, Donna
Zhang and Mark Hannink found that ectopically-expressed Keap1 in
which C151 in the BTB domain was mutated to a Ser is able to repress
Nrf2 even upon sulforaphane treatment, thus implicating C151 as one of
the sites which was specifically responsive to sulforaphane (Zhang and
Hannink, 2003). Michael McMahon and John Hayes confirmed C151 as
a target for sulforaphane by use of the biotin-switch technique, and fur-
ther demonstrated by performing molecular modeling and mutagenesis
experiments that C151 is particularly highly reactive as it is spatially
surrounded by basic amino acids (H129, K131, R135, K150, and H154)
which facilitate electrophilic addition to C151; indeed a mutant of
Keap1 in which K131, R135, and K150 were replaced by Met residues
had a greatly reduced sensor activity (McMahon et al., 2010). A model
by Simon Fourquet and Michel Toledano predicted that C151 is remotely
positioned from both the BTB dimerization interface and Cul3, and also
implicated the basic amino acid environment in the increased reactivity
of this cysteine (Fourquet et al., 2010). Based on mutagenesis analysis,
Aimee Eggler and AndyMesecar proposed an alternativemodel whereby
large residues at position 151 cause steric clashes that lead to alteration of
the Keap1–Cul3 interaction, ultimately resulting in impaired ability of
Keap1 to target Nrf2 for ubiquitination (Eggler et al., 2009). Mass-
spectrometry approaches have shown that, depending on the experimen-
tal conditions, in addition to C151, sulforaphane can also modify other
cysteines within Keap1, including cysteines residing in the Kelch domain
(Eggler et al., 2007; Hong et al., 2005a; Hu et al., 2011).
Following its isolation, sulforaphane was evaluated for the ability to
induce the Nrf2-dependent enzymes NQO1 and GST in vivo. The activi-
ties of NQO1 and GST were upregulated in liver, forestomach, glandular
stomach, small intestine, and lung of mice (Zhang et al., 1992), and in
liver, colon, and pancreas, and bladder of rats (Matusheski and Jeffery,
2001;Munday andMunday, 2004; Zhang et al., 2006) following oral ad-
ministration of sulforaphane. In contrast to wild-type animals, feeding
sulforaphane in the diet for 14 days at a dose of 3 μmol/g diet did not
affect the activities of NQO1 and GST in the small intestine of Nrf2-
deficient mice (McMahon et al., 2001), implicating the Keap1/Nrf2
pathway as the main target and mediator of the inducer activity of the
isothiocyanate. These efficacy studies are supported by investigations
testing the ability of sulforaphane to protect against disease, first in a
model of mammary carcinogenesis in Sprague–Dawley rats treated
with single doses of the chemical carcinogen 9,10-dimethyl-1,2-
benzanthracene (DMBA) (Zhang et al., 1994). It was found that oral ad-
ministration of sulforaphane at doses of 75 or 150 μmol per day for
5 days, namely 3 days before, the day of, and the day after carcinogen
exposure, decreased the incidence, multiplicity, and weight of the
tumors. Since this initial animal experiment, sulforaphane has been
used and shown to be an effective protective agent in numerous preclin-
ical models of gastric, intestinal, prostatic, pulmonary, cutaneous and
bladder cancers in animals, and in xenograft models of human tumors
[reviewed in (Dinkova-Kostova, 2013)]. Furthermore, sulforaphane- or
glucoraphanin-rich broccoli preparations have been and currently are
in several human studies, ranging from healthy human subjects to pop-
ulations at high risk for developing disease conditions [reviewed in
(Dinkova-Kostova and Kostov, 2012) and registered at clinicaltrials.gov].
Measuring protein–protein interactions with fluorescence lifetime
imaging microscopy
Resolution limits in conventional optical microscopy
Fluorescence microscopy is a powerful technique that has become
central in the study of the structure and function of biological speci-
mens. This is due in large part to its specificity and versatility. Although
an understanding of structure has proved an important tool in under-
standing function while offering a mechanism to interrogate cells in
the living state, conventional approaches are limited on the lateral
axis to approximately half the wavelength of emitted light (for reviews
see Stephens and Allan, 2003 and Lichtman and Conchello, 2005).
Biological processes typically involve the action and regulation of
multiprotein complexes and hence a key goal in most areas of cell biol-
ogy is the characterization of the protein components within multi-
subunit complexes through the reliable identification of specific protein
interaction partners and the study of their dynamics. This has necessi-
tated an approach that provides spatial information at an order of mag-
nitude greater than can be achieved with standard imaging approaches
(Chusainow et al., 2005). Indeed, to provide evidence of protein–protein
interaction, it is required to measure the proximity of proteins with
a resolution from 1 to 10 nm. This is simply not possible by using con-
ventional fluorescence microscopy where the resolution of the light
microscope is limited to ~250 nm laterally and ~500 nm axially. This
limitation imposed by the visible light resolution can be overcome by
the Förster resonance energy transfer (FRET) technique (Herman,
1989).
Förster resonance energy transfer (FRET) is the non-radiative trans-
fer of excited-state energy from onemolecule (named the donor) to an-
other nearby molecule (the acceptor) (Fig. 3) (Clegg, 1996; Förster,
1965). FRET has proved a popular technique, increasing the spatial res-
olution of the fluorescence microscope to below 10 nm. FRET improves
the spatial resolution because it relies on the close physical interaction
of two fluorophores (the donor and the acceptor). Indeed, as the effi-
ciency of energy transfer from the donor to the acceptor is dependent
on the inverse of the sixth power of the distance separating them,
FRET does not occur if the distance between these fluorophores exceeds
10 nm. Two further criteria must also be met: the emission spectrum of
the donormust overlap the excitation spectrumof the acceptor, and the
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Fig. 2. The myrosinase reaction. In the intact plant, the isothiocyanate sulforaphane is present as an inert precursor, the glucosinolate glucoraphanin. The hydrolysis of glucoraphanin is
catalyzed by myrosinase which normally is compartmentalized in adjacent plant cells. Enzyme and substrate come in contact upon plant injury. As a result of the myrosinase-
catalyzed hydrolysis, an unstable aglucone is formed first, and glucose is liberated. Depending on the reaction conditions, a series of final products can result, and the isothiocyanate
sulforaphane represents one major product.
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donor and acceptor must be appropriately orientated to allow energy
transfer. Three methods for measuring FRET are routinely used: accep-
tor photobleaching, sensitized emission, and fluorescence lifetime im-
aging microscopy (Piston and Kremers, 2007; Sekar and Periasamy,
2003).
Limitations of acceptor photobleaching and sensitized emission
It is worth noting the limitation of the first two of these approaches.
In acceptor photobleaching, FRET can be measured by selectively
photobleaching the acceptor molecule in order that energy from the
donor can no longer be transferred to the acceptor. This leads to an in-
crease in fluorescence intensity of the donor molecule. Although this
is relatively straightforward in practice, not only can photobleaching
of the acceptor cause photodamage to the sample, but in live-cell
studies there is a significant risk that the FRET measurement will be
invalidated by recovery of the acceptor fluorophore. In addition, this ap-
proach generally only measures FRET at a single predefined location,
rather than at every pixel throughout the cell. As a result, acceptor
photobleaching is not suitable for either time-lapse FRET measure-
ments, or for detailedmapping of FRET locations at different siteswithin
a cell. The second option, to measure FRET by sensitized emission, re-
quires that the donor molecule is excited and fluorescence is measured
in the acceptor channel only. In this case the donor molecule enters an
excited state but transfers its energy to the acceptor rather than emit-
ting light. This energy transfer elicits excitation of the acceptormolecule
leading to fluorescence emission at a longer wavelength. The emission
of light in the spectral range of the acceptor is then used as a measure
of FRET. In practice, a fraction of this measured fluorescence will be
due to direct excitation of the acceptor from the light used to excite
the donor, and a fraction of measured fluorescence will be from fluores-
cent light coming from thedonor. This cross-talkmust be carefullymea-
sured and excluded, which can be difficult or, in the case of samples
with high variation in each fluorophore concentration, most likely im-
possible to control (Swift and Trinkle-Mulcahy, 2004).
Advantages of FLIM–FRET
The fluorescence lifetime imaging microscopy (FLIM) approach
can be used to measure energy transfer and has the advantage of
circumventing the fundamental problems associatedwith the two alter-
native methods previously described. When a fluorescent molecule ab-
sorbs a quantum of light, a valence electron is boosted into an excited
state and returns to the ground state by: emitting a fluorescence pho-
ton, converting the energy internally, or transferring the energy to the
environment, or a combination of some of these. In FLIM, the lifetime
of the fluorescent event (i.e. the time it takes for the fluorophore to
become excited and return to the ground state) is measured. The
fluorescence lifetime of a fluorophore is an intrinsic property of the
fluorophore that occurs on a nanosecond-time scale. Molecular excita-
tion is stochastic, but the lifetime of a population of molecules can be
plotted. If a large number of fluorescent molecules are excited by a
short laser pulse, the time taken for fluorescence to decay can be plotted
as a single exponential curve (Fig. 4A). Assuming that little or no energy
is transferred to the environment, the fluorescence lifetime described
by this decay curve is considered as the natural fluorescence lifetime.
If energy is transferred to the environment, thefluorescence lifetimede-
creases. For almost all fluorophores, the rate of energy transfer from an
electron in the excited state to the environment depends on the local
chemical environment such as the concentration of ions, oxygen, pH
Fig. 3. Detection of Förster resonance energy transfer (FRET) by fluorescence lifetime imaging microscopy (FLIM) between EGFP–Nrf2 and Keap1–mCherry fusion proteins. (Left) EGFP–
Nrf2 and free mCherry fluorescent proteins do not interact (left, top). On absorbing 2-photons excitation light, the donor fluorophore changes from ground state (S0) to the excited state
(S2), as illustrated in the simplified Jablonski energy-level diagram (left, bottom). This is followed by emission of a photon (fluorescence) during the next few nanoseconds (τD). (Middle)
EGFP–Nrf2 interacts with one monomer of the Keap1–mCherry dimer, and forms a Keap1–Nrf2 complex in an “open conformation” (middle, top). The two fluorescent fusion proteins
interact, illustrating the effect of energy transfer on donor fluorescence lifetime. As the Jablonski diagram shows (middle, bottom), deactivation from the donor excited state can occur
either by fluorescence (downward-pointing arrow), or through the radiationless transfer of energy to the acceptor by FRET. The occurrence of FRET is detectable by a decrease in the
donor fluorescence lifetime (τFRET). (Right) EGFP–Nrf2 interacts with both monomers of the Keap1–mCherry dimer and forms a Keap1–Nrf2 complex in a “closed conformation”
(right, top). As illustrated by the thicker black arrow the non-radiative transfer of energy to the acceptor is stronger due to the closer proximity between EGFP–Nrf2 and Keap1–mCherry
proteins. Consequently, a more drastic decrease in the donor fluorescence lifetime (τFRET) is measured (right, bottom).
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value or the binding of proteins in a cell. FRET is an exceptionally strong
quencher of fluorescence. Because there is a direct relation between the
concentration of fluorescence quenchers and the fluorescence lifetime
of the fluorophore, FLIM is particularly well suited for quantitative
FRET analysis (Becker, 2012; Borst and Visser, 2010; Lakowicz, 2006).
Where FLIM–FRET proves most advantageous, is that it is generally
insensitive to the relative concentrations of the fluorophores tagged to
the proteins of interest and can be done in cell lines transiently express-
ing either one or both of the fluorophore-tagged proteins. The total de-
crease of the donor fluorescence lifetime depends both on the distance
between the donor and acceptor and the fraction of interacting donor
molecules. In FRET situations, a double exponential fluorescence life-
time model is used to describe the decay time of the donor molecule,
with a slow lifetime component representing the fraction of non-
interacting donormolecules and a fast lifetime component representing
the fraction of interacting donor molecules (Fig. 4B). FLIM–FRET pro-
vides a unique measurement of the amount of FRET occurring for
every pixel in an image, offering an exquisite level of spatial detail. Fur-
thermore, it is not affected significantly by either the relative concentra-
tions of the interacting proteins, or by their diffusion rates. FLIM–FRET
Fig. 4. Time-correlated single photon counting (TCSPC) FLIM principle. The time-correlated single photon counting (TCSPC) FLIM system is based on the detection of single photons of a
periodical light signal, followed by themeasurement of the detection times of the individual photons, and the reconstruction of thewaveform from the individual timemeasurements. For
each pixel during the scanning acquisition time, when a single photon is detected from the donor EGFP–Nrf2 in the absence or in the presence of the acceptor Keap1–mCherry (A and B,
respectively), the time of the corresponding detector pulse ismeasured. Each detection event is recorded inmemory, associatedwith its specific detection time (left panels). Over time, the
waveform of the optical pulse builds up, corresponding to a histogram presenting the number of photons recorded for each detection time interval (right panels). In the absence of FRET
(A), a single exponentialmodel is used tofit the experimental donor fluorescence decay. This analysis delivers the lifetime value τD. In a FRET situation (B), a double exponentialmodel can
approximate the resulting donor fluorescence decay, with a slow lifetime component τD from the fraction of non-interacting EGFP–Nrf2 donor molecules (blue part of the fit) and a fast
component from the fraction of interacting EGFP–Nrf2 donormolecules (red part of thefit). The composition of the donor decay function iswritten on the right. Double exponential decay
analysis delivers the lifetimes, τD and τFRET, and the intensity factors, a and b, of the two decay components. For each condition, a false-color image, displaying the distribution of the fluo-
rescence lifetime for each pixel of the image, is shown.
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can also provide additional information about the fraction of proteins
engaged in interactions and their mean separation distance (Llères
et al., 2007; Yasuda, 2006). For all these reasons, FLIM–FRET is now rou-
tinely used for dynamic measurements of protein–protein interactions
and signaling pathways in living cells (Batisse et al., 2013; Ellis et al.,
2008; Ems-McClung et al., 2013; Janes et al., 2009; Li et al., 2010).
The cyclic sequential attachment and regeneration model of
Keap1-mediated degradation of Nrf2
To gain a deeper understanding of the mechanism through which
Nrf2 is targeted for ubiquitination by Keap1, we recently developed a
FLIM–FRET-based system in cells expressing Keap1–mCherry and
EGFP–Nrf2 fusion proteins (Baird et al., 2013). This approach allowed
us to examine the dynamics of theKeap1:Nrf2 interaction in the endog-
enous environment of single live cells. FRET has previously been used to
show that in the basal state, Nrf2 binds to Keap1 in the cytoplasm
(Li et al., 2006). Recently, this approach has also been adapted for use
in a high-throughput assay to identify direct inhibitors of the Keap1:
Nrf2 interaction in vitro (Schaap et al., 2013). However, FRET has not
previously been used to study the dynamismof the Keap1: Nrf2 interac-
tion in live cells, or to determine how this interaction is affected by
inducers.
Using this system, we were able to calculate the FRET efficiency
(E-FRET) within the Keap1–mCherry: EGFP–Nrf2 protein complex in
such away as to be able to “see” changes in the conformation of the pro-
tein complex. Surprisingly, the E-FRET distribution data revealed that
there were two distinct FRET interaction populations, centered at 13%
E-FRET and 21% E-FRET, respectively, implying that the Keap1: Nrf2
complex may be found in two different conformations in the basal
state (Fig. 5A). In order to understandwhat these two FRET interactions
represent, we generated a number of Nrf2 mutants which bound with
either a reduced or increased affinity for Keap1 (Baird et al., 2013).
Together, the mutant-derived data suggest that in the basal state the
Keap1: Nrf2 complex is found in two distinct conformations: one in
which only the high affinity “ETGE” motif of Nrf2 is bound to Keap1,
Fig. 5. Inducers promote the formation of the closed conformation of the Keap1–Nrf2 complex. HEK293 cells were transfectedwith EGFP–Nrf2+ Keap1–mCherry and imaged 24 h later.
Both the EGFP lifetime and FRET efficiency (E-FRET) were quantified in individual cells which were imaged twice, once in the basal state (A, C) and once again after 1-h treatment with
either 5 μM sulforaphane (SFN) (B) or 10 μM STCA (D). The left column shows pictorial representations of the E-FRET where the color of the cell corresponds to the FRET efficiency ac-
cording to the legend below the image, ranging from 0% to 30%. The second column shows the E-FRET from each pixel of the image plotted on a graph, with E-FRET on the x-axis and
frequency on the y-axis. The graphs show that both SFN and STCA alter the FRET efficiency to favor the closed conformation (21% E-FRET population) of the Keap1–Nrf2 complex. This
change can also be seen in the images in the first column, as both (B) and (D) contain more yellow and less green than (A) and (C). The third column shows a pictorial representation
of the EGFP lifetime data from which the E-FRET data are derived. In these images, the color of the cell corresponds to the lifetime of EGFP, ranging from 1.9 ns to 2.6 ns as indicated
on the legend below the image. The right column shows the lifetime data from each pixel of the image plotted on a graph, with lifetime on the x-axis and frequency on the y-axis. The
graphs of the lifetime data show that in the presence of either SFN (B) or STCA (D), the lifetime of EGFP is reduced, manifesting as a shift in the EGFP lifetime to the left relative to the
basal state shown in (A) and (C). This lifetime reduction is shown pictorially in the third column, where in the presence of either inducer the cells become yellow/orange and less
green/yellow. Together these data show that in response to SFN or STCA, the lifetime of EGFP–Nrf2 is reduced, coupled with a change in E-FRET corresponding to an increase in the for-
mation of the closed conformation of the Keap1–Nrf2 complex.
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representing the 13% E-FRET population (and termed the “open confor-
mation”) and a second in which both the “DLG” and “ETGE” motif are
bound to the Keap1 dimer, representing the 21% E-FRET population
(and termed the “closed conformation”). Thus, the FLIM–FRET data sug-
gested that the Keap1: Nrf2 complex in vivo exhibits a greater degree of
dynamism than previously anticipated.
As changes in FRET can be directly related to changes in the conforma-
tion of the protein complex in which the fluorophores are found, we also
analyzed the E-FRET of the Keap1: Nrf2 complex in the induced state.We
used two inducers which differ in potencies and target different cysteines
of Keap1, i.e., sulforaphane, which targets C151 (McMahon et al., 2010;
Zhang and Hannink, 2003) and the sulfoxythiocarbamate STCA, which
targets C273, C288, and C613, and is 25-times less potent than sulforaph-
ane (Ahn et al., 2010). In the presence of sulforaphane (Fig. 5A,B) or STCA
(Fig. 5C,D) the E-FRET was significantly altered, such that in the induced
state, the Keap1: Nrf2 complex accumulated in the closed conformation
(Fig. 5B,D), suggesting a functional change in the complex in response
to inducers. Thus, both sulforaphane and STCA function to change the bal-
ance between the open and closed conformations of the Keap1: Nrf2
complex, whereby in the induced state, the closed conformation is
favored.
The fact that inducers lead to a change in the conformation of
the Keap1–Nrf2 complex suggests that the complex can “move” be-
tween the open and closed conformation states. In order to gain an
understanding of how this dynamism is achieved, we manipulated the
synthesis and degradation rates of Nrf2, through the use of the transla-
tion inhibitor cycloheximide (CHX) and the proteasome inhibitor
MG132. Upon treating cells with either CHX or MG132 we observed a
reduction in the abundance of the open conformation and a correspond-
ing increase in the closed conformation (Baird et al., 2013).
Together, these data indicate that the Keap1-mediated ubiquitination
of Nrf2 follows a cycle as illustrated in Fig. 6A. In the basal state, newly-
translated Nrf2 binds to one member of a free Keap1 dimer through its
high affinity “ETGE”motif to form the open conformation. The existence
of this conformation is supported by structural studies which have
shown that the DLG motif binds to Keap1 in a distinct mode from the
ETGEmotif, with “fast on fast off” kinetics (Fukutomi et al., 2014). Subse-
quent to this, the low affinity “DLG” motif of Nrf2 binds to the other
member of the Keap1 dimer to form the closed conformation. Once the
two-site binding is achieved, the lysine residues in the α-helix between
the “DLG” and “ETGE” motifs are in the correct orientation to be
ubiquitinated by the Keap1-dependent E3-ligase (McMahon et al.,
2006; Tong et al., 2006a, 2006b). Upon ubiquitination, Nrf2 is released
from Keap1 and degraded by the proteasome, while the regenerated
free Keap1 dimer is able to bind newly-translated Nrf2 allowing the
cycle to continue. We call this model the “cyclic sequential attachment
and regeneration” or “conformation cycling”model of Keap1-mediated
Nrf2 degradation.
Fig. 6.Nrf2-dependent regulation of cytoprotective gene expression. (A) The cyclic sequential attachment and regeneration model of Keap1-mediated degradation of Nrf2, with Keap1 in
blue andNrf2 in yellow. (B) Inducers produce a conformational change inKeap1 and thus uncouple the formation of the closed conformation of the complex fromNrf2 ubiquitination. This
allowsnewly-translatedNrf2 to translocate to thenucleus and activate cytoprotective gene expression. (C) TheKeap1-dependent cycle of Nrf2 degradation isfinely balanced such that any
increase inNrf2 level, through enhanced transcription, or decrease in Keap1 level, by promoter hypermethylation ormiRNA activity, leads to the saturation of Keap1 allowing the freeNrf2
to activate target gene expression. (D)When the Keap1–Nrf2 complex is in the open conformation, the Kelch domain of Keap1 and theDLGmotif of Nrf2 are exposed and thus can bind to
other proteins. This binding inhibits the formation of the closed conformation, and thus Nrf2 ubiquitination, and therefore allows other signaling pathways to regulate Nrf2 activity.
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Our findings suggest that inducers function to stabilize Nrf2 by pro-
moting the formation of the closed conformation of the Keap1–Nrf2
complex. This outcome seems counterintuitive as the closed conforma-
tion is associated with ubiquitination of Nrf2 in the basal state, yet with
stabilization of Nrf2 in the induced state. Notably, these two ideas are not
contradictory as the E-FRET data reflect the distance between Nrf2 and
the Kelch domain of Keap1, but not the relative location of the
ubiquitination machinery of the Keap1 complex. It has been shown
that when inducers bind to the sensor cysteines of Keap1 they lead to a
conformational change in the protein, but not to the dissociation of the
Keap1–Nrf2 or the Keap1–Cul3 complex (Baird and Dinkova-Kostova,
2013; Dinkova-Kostova et al., 2005; Eggler et al., 2005; Li et al., 2012).
The inducer-mediated conformational change in the Keap1 structure
may alter the positioning of Nrf2 relative to the E2-ubiquitination ma-
chinery such that Nrf2 can no longer be ubiquitinated and/or degraded
by the Keap1 complex (Fig. 6B). Thus, although in the induced state the
Keap1: Nrf2 complex is still in the closed conformation, inducer-
dependent conformational changes in Keap1mean that Nrf2 can no lon-
ger be targeted for degradation. Consequently, Nrf2 is not released from
Keap1, the free Keap1 dimer is not regenerated, and it can be proposed
that, in the presence of electrophiles which target cysteine sensors of
Keap1, Nrf2 acts as a “suicide” substrate to inactivate Keap1. The
newly-translated Nrf2 is then unable to bind to Keap1 and thus is free
to translocate to the nucleus and activate expression of cytoprotective
genes. This mechanism explains why in the absence of new translation,
Nrf2 is not stabilized by inducers, and Nrf2-dependent target genes are
not upregulated (Kobayashi et al., 2006; Kwak et al., 2002; Sekhar
et al., 2000; Shay et al., 2012).
Implications of the cyclical nature of the Keap1-mediated
degradation of Nrf2
Mutations in either Keap1 or Nrf2 destroy two-site binding in tumors
The physiological importance of the two-site binding and formation
of the closed conformation is illustrated by the mutation spectrum of
Nrf2 in human cancer. Persistent upregulation of Nrf2-dependent
genes is frequently exploited by cancer cells, and promotes their surviv-
al and resistance to chemotherapy and radiation therapy: mutations in
KEAP1 or NRF2, which abrogate formation of the complex and lead to
Nrf2 accumulation and constitutive activation of the pathway, have
been detected in several tumor types, including lung, liver, breast,
kidney, ovarian, gall bladder and esophageal cancers (Abazeed et al.,
2013; Guichard et al., 2012; Konstantinopoulos et al., 2011; Nioi and
Nguyen, 2007; Ooi et al., 2013; Sato et al., 2013; Shibata et al., 2008a;
Shibata et al., 2008b; Shibata et al., 2011). Comprehensive genomic
characterization of squamous cell lung cancers (2012) has identified
mutations inNRF2, KEAP1, or CUL3 in 34% of 178 lung squamous cell car-
cinomas. According to the COSMIC database (http://cancer.sanger.ac.uk/
cancergenome/projects/cosmic/), there have been 219 non-synonymous
mutations found in theNRF2 gene, of which 84% are found in or adjacent
to either the “DLG” or “ETGE” motifs. In one study in which NRF2 was
found to be mutated in 12% of lung cancer patients, all 14 mutations
identified were in either the “DLG” or “ETGE” motifs (Shibata et al.,
2008b). These in vivo data highlight the fact that the formation of the
closed conformation is of fundamental importance to the Keap1-
mediated Nrf2 regulation.
Interestingly, a novel class of Keap1 cancer mutations have recently
been identifiedwhich do not lead to the destruction of two-site binding.
Instead, the newly termed “superbinder” Keap1 mutants bind to Nrf2
with a greater affinity than wild-type Keap1, yet are unable to inhibit
Nrf2-mediated gene expression (Hast et al., 2014). These data from
human tumors complement the conformation cycling model, and sug-
gest that similar to small-molecule Nrf2 inducers, the “superbinder”
mutants may lead to an accumulation of the Keap1: Nrf2 complex in
the closed conformation, allowing newly-translated Nrf2 to bypass the
“saturated” Keap1 and translocate into the nucleus.
Stoichiometric imbalance
As the Keap1-dependent destruction of Nrf2 follows a cycle, the
relative abundance of each protein will impact on the efficiency of the
ubiquitination of Nrf2. For example, an increase in the amount of
Keap1 relative to Nrf2 will tip the balance in favor of Nrf2 ubiquitination,
as the increased abundance of Keap1will be able to bind the cellular pool
of Nrf2more efficiently. Conversely, an increase in expression of Nrf2 rel-
ative to Keap1 will lead to the saturation of Keap1 binding and subse-
quent increase in the Nrf2 protein level (Fig. 6C). Indeed this has been
shown to be the case using amousemodel to examine Nrf2 gene dosage
effects (Suzuki et al., 2013). In this study, Suzuki et al. found that a reduc-
tion in the level of Nrf2 expression resulted in decreased Nrf2 activity in
both the basal and induced states. Conversely, an upregulation in Nrf2
expression led to an increase in Nrf2 activity in both the basal and
induced states, suggesting that Nrf2 activity is governed by a balance
between protein synthesis and destruction due to the limited capacity
of Keap1 to target Nrf2 for ubiquitination.
This Nrf2 gene dosage effect has important implications for human
disease, particularly in cancer. For example, in a somatic copy number
variation (SNCA) pan-cancer analysis, NFE2L2, the gene encoding Nrf2,
was identified as one of the loci recurrently gained in human tumors
(Zack et al., 2013). In addition, in a mouse model of pancreatic cancer
it was shown that oncogenic K-Ras or B-Raf signaling resulted in amod-
est (b2-fold) upregulation in Nrf2 expression, leading to an increase in
Nrf2 protein level, and Nrf2-dependent gene transcription, which ulti-
mately contributed to a cellular detoxification program that aided tu-
morigenesis in this model (DeNicola et al., 2011). Conversely, a
reduction in the amount of Keap1 protein would have a similar effect,
as it will become oversaturated with a basal level of Nrf2, resulting in
the increased transcription of Nrf2-target genes in the absence of either
Nrf2 upregulation or oxidative stress. One such mechanism through
which the level of Keap1 expression may be reduced in the cell is
through promoter hypermethylation. Indeed, in cell lines and tumors
from patients with gliomas, lung cancer, colorectal cancer, prostate can-
cer, and head andneck cancer, hypermethylation of the Keap1promoter
has been observed (Hanada et al., 2012; Martinez et al., 2014;
Muscarella et al., 2011; Wang et al., 2008; Zhang et al., 2010). This
leads to a reduction in Keap1 expression, and in the case of prostate
and colorectal cancer cells, an increase in the expression of Nrf2-target
genes. Similarly, it has been shown that in breast cancer cells, the
microRNA miR-200a is able to target a sequence in the 3′UTR of the
Keap1 mRNA, leading to a reduction in the level of Keap1 mRNA and
protein, and a concomitant increase in the level of Nrf2 and increased
transcription of the Nrf2-target gene NQO1 (Eades et al., 2011). The
physiological relevance of the stoichiometric imbalance of Keap1 and
Nrf2 is well illustrated in non-small cell lung cancer (NSCLC). Tumors
which are both positive for Nrf2 and show low or absent Keap1 expres-
sion are significantly associated with a reduced 5-year overall survival
rate (Solis et al., 2010).
Interestingly, both cysteine-reactive inducers and non-canonical
activation of Nrf2 may also impact the relative abundance of Keap1
upon pathway activation. It has previously been shown that in the
presence of inducers, Keap1 and not Nrf2, becomes the substrate
for ubiquitination (Hong et al., 2005b; Zhang et al., 2005). The
ubiquitination of Keap1 leads to a reduction in its half-life in the induced
state, and thus oncemodifiedby electrophiles, the relative abundance of
Keap1within the cell is reduced (Taguchi et al., 2012). Similarly, binding
of p62 to Keap1 not only inhibits the formation of the closed conforma-
tion, but also targets Keap1 for degradation through the autophagy
pathway (Bae et al., 2013; Taguchi et al., 2012). These data suggest
that the rapid accumulation of Nrf2 in response to either electro-
philes and oxidants, or other signaling pathways occurs due to the
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simultaneous inactivation of Keap1-mediated ubiquitination of Nrf2,
and a decrease in the level of Keap1. Together, these complementary
mechanisms facilitate the rapid and robust induction of cytoprotective
gene expression.
Protein competition
One consequence of the “conformation cycling” model is that the
Keap1–Nrf2 complex must spend some of its time in the open confor-
mation before progressing to the closed conformation.One simple ques-
tion which arises from these data is: what is the biological function of
the open conformation? We believe that the Keap1–Nrf2 complex
forms the open conformation in order to provide an additional opportu-
nity for other signaling pathways and cellular inputs to regulate Nrf2 ac-
tivity by inhibiting the formation of the closed conformation (Fig. 6D).
Thus competitive binding of other proteins to Keap1 provides another
layer by which Nrf2-dependent gene expression can be regulated.
The first protein which was found to positively regulate Nrf2-
dependent gene expression through competitive inhibition of two-site
binding was the oncoprotein prothymosin α (Karapetian et al., 2005).
Prothymosin α was found to contain an “ENGE”motif which is similar
to the high affinity “ETGE” of Nrf2 (Padmanabhan et al., 2008). Through
thismotif, prothymosinαmay be able to competewith theDLGmotif of
Nrf2 for binding to the Kelch domain of Keap1, leading to a loss of the
formation of the closed conformation and the upregulation of Nrf2 tar-
get gene expression. A genomic screen for activators of Nrf2 found that
p62 and DPP3 could also positively regulate Nrf2-dependent gene ex-
pression (Liu et al., 2007). Like prothymosinα, both p62 and DPP3 com-
pete with Nrf2 for binding to Keap1, suggesting that this may be a
common non-canonical mechanism by which cytoprotective gene ex-
pression can be regulated (Hast et al., 2013; Komatsu et al., 2010). In-
deed, the list of proteins which are able to compete for binding with
Nrf2 has increased, suggesting that multiple signaling pathways can
converge on Nrf2 to regulate its activity (Table 1). This list includes
human IKKβ, which has been shown to bind to Keap1 (Kim et al.,
2010; Lee et al., 2009), although the consequences for Nrf2 activation
have not been examined. In addition, one of the proteins whichmay in-
hibit the formation of the closed conformation, p21, binds not to the
Kelch domain of Keap1, but directly to the DLG motif of Nrf2, and in
doing so inhibits the two-site binding (Chen et al., 2009). This suggest
that multiple mechanisms may be used to inhibit the formation of the
closed conformation of the Keap1: Nrf2 complex, and thus inhibit Nrf2
ubiquitination.
The physiological consequences of this competitive bindingmode of
Nrf2 regulation are best understood in the case of p62.When autophagy
is suppressed in the cell, p62 accumulates and binds to the Kelch do-
main of Keap1 through its KIR domain (Komatsu et al., 2010). Notably,
by use of fluorescence polarization, it has been shown that a peptide
based on the Keap1-binding motif of p62 interacts with the Kelch do-
main of Keap1, and curiously, the affinity of this interaction is 10-fold
stronger when the p62-based peptide is phosphorylated (Hancock
et al., 2012). In agreement, phosphorylation of S351 within the KIR
domain by the mechanistic target of rapamycin complex 1 (mTORC1)
kinase increases the affinity of p62 for Keap1 by 30-fold (Ichimura
et al., 2013). During both mitophagy and xenophagy, p62 becomes
phosphorylated at S351, and co-localizes with Keap1. This results in
both the nuclear accumulation of Nrf2, and the upregulation of the
Nrf2-target genes NQO1 and heme oxygenase 1 (Ichimura et al.,
2013). Similarly, in mouse livers the suppression of autophagy leads to
the accumulation of phospho-p62, its colocalization with Keap1, and
the upregulation of Nrf2 target gene expression (Ichimura et al.,
2013). Together, these data clearly demonstrate that non-canonical
activation of Nrf2 through inhibition of the formation of the closed con-
formation of the Keap1: Nrf2 complex has important physiological
consequences.
Comparison of the “conformation cycling” model with the “hinge
and latch”model
The “conformation cycling” model builds upon the previously
proposed “two-site binding” or “hinge and latch” model of Keap1-
mediated Nrf2 degradation (Fukutomi et al., 2014; Tong et al., 2006a,
2006b; Tong et al., 2007). The “hinge and latch”model postulates that,
as both cancer-related mutations and non-canonical activators, such
as p62, function to inhibit the two-site binding, inducers may function
in the same way, and it has been proposed that in the presence of in-
ducers, the low affinity DLG motif is released by Keap1. However,
there are currently no experimental data which have demonstrated
that the release of the DLGmotif occurs. In addition, it is difficult to rec-
oncile somepublished datawith the “hinge and latch”model as it is cur-
rently understood. For example, McMahon et al. showed that if the low
affinity DLGmotif ismutated into an additional high affinity ETGEmotif,
Nrf2 can still be stabilized by the inducer sulforaphane (McMahon et al.,
2006). This suggests that the release of the low affinity motif (which is
not present in this mutant Nrf2) is not required for Nrf2 stabilization.
In addition, isothermal titration calorimetry (ITC) experiments carried
out with full-length Keap1 protein and the Neh2 domain of Nrf2 show
that inducers do not lead to a reduction in the affinity of these two pro-
teins, as would be predicted by the “hinge and latch” model (Eggler
et al., 2005). It has also been shown that inducers, including sulforaph-
ane, promote Nrf2 association with Keap1, rather than dissociation
(Li et al., 2012). Importantly, the available structural data, as well as
the cancer-related mutations and non-canonical stabilization of Nrf2
data support both the “hinge and latch” model and the “conformation
cycling” model, and thus there are no published data which support
the “hinge and latch”model that do not also support the “conformation
cycling”model.
The structural data suggest that the ETGE andDLGmotifs each bind to
Keap1 in a distinct manner, and that the “rapid association–dissociation”
nature of the DLG interactionmeans that it is sometimes bound to Keap1
and sometimes unbound (Fukutomi et al., 2014). This conforms exactly
to the open and closed conformation of the Keap1: Nrf2 protein complex
which we observed in our live-cell assay. Non-canonical activation of
Nrf2 by proteins such as p62 support the significance of this finding,
and suggest that Nrf2 forms the open conformation in order to allow
multiple modes of regulation. The “hinge and latch”model is also sup-
ported by cancer-related mutations in Nrf2, where mutations in either
the ETGEmotif or the DLGmotif are sufficient to inhibit two-site binding,
resulting inNrf2 stabilization. Again, these data equally support the “con-
formation cycling” model, as here two-site binding is also required for
Nrf2 ubiquitination, so mutation of either binding motif will inhibit
Nrf2 ubiquitination.
The “conformation cycling”model suggests that the inactivation of
Keap1 by cysteine-reactive inducers is sufficient for Nrf2 stabilization.
This explains why the presence of a second high affinity ETGE motif in
Nrf2 still allows the protein to be stabilized, despite the fact that the
“weak” binding motif (which is absent in this mutant) is not released.
In addition, the “conformation cycling”model also explainswhy the iso-
thermal calorimetry data showed no difference between the basal and
Table 1
Examples of proteins which interact with Keap1 or Nrf2.
Protein Binding partner Motif Reference
Prothymosinα Keap1 ENGE Karapetian et al. (2005) and
Padmanabhan et al. (2008)
p21 Nrf2 KRR Chen et al. (2009)
p62 Keap1 PSTGEL Komatsu et al. (2010)
Palb2 Keap1 LDEETGE Ma et al. (2012)
WTX Keap1 ETGE Camp et al. (2012)
PGAM5 Keap1 ESGE Lo and Hannink (2006, 2008)
DPP3 Keap1 ETGE Hast et al. (2013)
IKKβ Keap1 ETGE Kim et al. (2010) and Lee et al. (2009)
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induced state: namely because cysteine-reactive inducers do not affect
the way by which Nrf2 binds to Keap1, but instead lead to the inactiva-
tion of Keap1-mediated Nrf2 ubiquitination.
One prediction that can be made based on the “conformation cy-
cling”model is that in addition to mutations in human tumors leading
to the destruction of the two-site binding, a subset of mutations in
either Keap1 or Nrf2 may lead to an increase in the affinity of the two
proteins. According to the cyclic model, an increased affinity of the
Keap1: Nrf2 complex will reduce the rate of Keap1 regeneration,
allowing newly-translated Nrf2 to translocate to the nucleus and acti-
vate cytoprotective gene expression. Interestingly, mutations have
been identified from human tumors in both Keap1 and Nrf2 which in-
crease the affinity of the mutant protein for its wild-type partner
(Fukutomi et al., 2014; Hast et al., 2014). The mechanism by which
these mutations may function is difficult to understand in light of the
“hinge and latch”model, but is in complete agreementwith the “confor-
mation cycling” model. Thus, the “conformation cycling” model con-
forms to all of the available data which also support the “hinge and
latch”model, and is also supported by data which until now, have not
been fully explained.
Conclusions
As the role of Nrf2 has expanded from cytoprotection to include reg-
ulating cell proliferation andmetabolism, the inputswhich activate Nrf2
activity have similarly diversified. Thus, Keap1-mediated Nrf2 activa-
tion is no longer limited to the sensing of exogenous electrophiles and
oxidants, but can be regulated by p53 activation, autophagy defects,
and changes in tricarboxylic acid (TCA) cycle enzyme activity (Adam
et al., 2011; Bae et al., 2013; Komatsu et al., 2010; Ooi et al., 2011).
The development of a FLIM–FRET system revealed that the Keap1:
Nrf2 complex is able to integrate these diverse cellular signals to regu-
late Nrf2 activity through both the canonical as well as non-canonical
pathways. This mechanism allows the cell to respond rapidly to multi-
ple numbers of environmental and cellular changes through the upreg-
ulation of Nrf2-dependent gene transcription.
Nrf2 binds to the Keap1 dimer through two distinct motifs
(McMahon et al., 2006; Tong et al., 2006a, 2006b). By use of Nrf2 mu-
tants we found that the complex exists in two distinct conformations
in the basal state, suggesting that the Keap1: Nrf2 complex is much
more dynamic than previously anticipated. In the design of our fusion
proteins, the relative positions of the fluorophores in the complex,
coupled with the dual binding sites in Nrf2, facilitated the discovery of
the conformational dynamism. These mechanistic considerations are
not unique to the Keap1: Nrf2 interactions, and many signaling path-
ways are mediated by dynamic protein dimer complexes, including
EGFR and Fbw7 (Dawson et al., 2005; Marianayagam et al., 2004;
Welcker and Clurman, 2007). Therefore, an approach analogous to
ours could be adapted to study other cellular pathways. Indeed, a
dimer of the E3-ubiquitin ligase Fbw7 binds to a monomer of its target
cyclin E through two distinct motifs, in a similar way to the Keap1:
Nrf2 complex (Hao et al., 2007; Welcker and Clurman, 2007). Use of
FLIM–FRET may reveal that the dynamic cyclic nature of the Keap1:
Nrf2 complex is not limited to this pathway and may represent a
more general mechanism through which other E3-ubiquitin ligases
target their substrates for ubiquitination and degradation.
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